Life Science Leader Blogs

  1. J&J’s Addition Of JLABS in New York City Creates Buzz At BIO CEO 2018
    2/16/2018

    Rob Wright interviews Kate Merton, head of Johnson & Johnson Innovation’s newly created JLABS in New York City.

  2. Jeremy Levin On BIO’s Efforts Toward Tackling The Opioid Crisis
    2/16/2018

    Rob Wright interviews Jeremy Levin, chairman and CEO of Ovid Therapeutics, about the BIO opioid crisis working group he is chairing.

  3. What Oppenheimer Is Doing To Support Healthcare Investors
    2/16/2018

    Rob Wright video interviews Michael Margolis, R.Ph, head of life sciences and co-head of healthcare investment banking at Oppenheimer & Co. Inc. during the 2018 BIO CEO & Investor Conference in New York.

  4. Why CytoSorbents Has The BIO CEO Investor Community Buzzing
    2/16/2018

    Rob Wright video interviews CytoSorbents’ CEO, Dr. Philip Chan, about CytoSorb, the company’s lead product described as a “Brita filter for your blood,” during the 2018 BIO CEO & Investor Conference in New York.

  5. Atreca Is Doing More Than Just Creating A Buzz At BIO CEO 2018
    2/16/2018

    Rob Wright video interviews Atreca CEO, Tito Serafini, during the 2018 BIO CEO & Investor Conference in New York about the company’s search for antigens that are driving successful immune responses in cancer patients.

  6. Gender Diversity In Leadership - How Does Biopharma Compare?
    2/12/2018

    How the 10 largest publicly traded biopharmaceutical companies compare to 10 of the largest publicly traded nonbiopharmaceutical companies in the area of gender diversity among executive leadership.

  7. Is It Time For Branded Biopharmaceuticals To Get Into The Business Of Generics?
    2/5/2018

    With President Trump’s recently announced focus on reducing the price of prescription drugs, perhaps it is time branded biopharmaceutical companies consider competing in other areas beyond just biosimilars (i.e., generic biologics).

  8. Does Drug Development Require A Passionate Commitment?
    1/26/2018

    Successful drug discovery and development requires a passionate commitment, something that can only be displayed during the breakout sessions at the J.P. Morgan annual healthcare conference.

  9. JPM — More Than A Gap In Gender
    1/24/2018

    While some continue to focus on the lack of gender diversity at the annual J.P. Morgan healthcare conference, GSK’s CEO, Emma Walmsley, notes that supporting diversity means doing more than just focusing on the “gender agenda.”

  10. Connectivity — The Beauty Of JPM And BTS
    1/22/2018

    The annual J.P. Morgan and Biotech Showcase conferences not only provide great networking opportunities, they expose you to interesting and cutting-edge companies to keep on your radar.